# Observational Retrospective Study To Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab in the Framework Of Use in Special Situations Prior to Commercialisation in Spain

> **NCT06487065** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 33 (actual)

## Conditions studied

- Severe Asthma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06487065
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-17
- **Primary completion:** 2024-10-25
- **Final completion:** 2024-10-25
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06487065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06487065, "Observational Retrospective Study To Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab in the Framework Of Use in Special Situations Prior to Commercialisation in Spain". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06487065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*